Acromegaly is associated with an enhanced mortality, with cardiovascular and respiratory
complications representing not only the most frequent comorbidities but also two of the main …

This review focuses on the systemic complications of acromegaly. Mortality in this disease is
increased mostly because of cardiovascular and respiratory diseases, although currently …

Impaired cardiovascular function has recently been demonstrated to potentially reduce life
expectancy both in GH deficiency and excess. Experimental and clinical studies have …

Acromegaly is caused by excess growth hormone (GH) secretion emanating from a
somatotroph adenoma. High GH and Insulin-like growth factor-1 (IGF-1) levels lead to acral …

Since their introduction into clinical practice, somatostatin analogs have been the medical
therapy of choice for the treatment of acromegaly. Therefore, considerable data exist on their …

Summary Background GH and IGF‐I affect cardiac structure and performance. In the general
population, low IGF‐I has been associated with higher prevalence of ischaemic heart …

The effects of a 12-to 24-month treatment with depot long-acting octreotide (OCT-LAR) on
hormone profile, tumor mass, and clinical symptoms were reported in 36 patients with active …

Although acromegaly is a rare disease, the clinical, economic and health-related quality of
life (HRQoL) burden is considerable due to the broad spectrum of comorbidities as well as …

The availability of recombinant human GH and somatostatin analogs has resulted in
widespread treatment for adults with GH deficiency (GHD) and those with GH excess …

Context: Persistently elevated GH and IGF-I levels are associated with increased mortality.
Their response to somatostatin analogs (SSA) is variable. Objective: The objective of this …